首页> 外文期刊>Bone marrow transplantation >Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen
【24h】

Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen

机译:使用降低的强度调理方案,同种异体干细胞移植后肝脏中度至严重静脉闭塞性疾病的发生率和危险因素

获取原文
获取原文并翻译 | 示例
       

摘要

The incidence and outcome of moderate-to-severe veno-occlusive (VOD) disease was analyzed in 271 consecutive patients with hematological malignancies who underwent allogeneic SCT (allo-SCT) using the same reduced intensity regimen (RIC). RIC consisted of fludarabine, BU and antithymocyte globulin (ATG). Twenty-four out of 271 patients (8.8%) developed VOD, which was severe in only 4 (1.4%) out of 24 cases. All four patients with severe VOD finally succumbed to their disease. In multivariate analysis, i.v. administration of BU was associated with significant reduced incidence of VOD as compared with per os administration. In conclusion, VOD remains a serious complication of allo-SCT using RIC regimens containing BU. Although the incidence of severe VOD is very low, the overall mortality rate in the group of patients with severe VOD remains extremely high and therefore novel treatment approaches are needed.
机译:在271名连续血液恶性肿瘤患者中分析了中度至严重的静脉闭塞(VOD)疾病的发病率和结果,所述血液恶性肿瘤患者使用相同的强度方案(RIC)进行同种异体SCT(Allo-SCT)。 RIC由氟氮胺,Bu和Antithymyte球蛋白(ATG)组成。 271名患者中的二十四个(8.8%)开发的VOD,24例中仅为4(1.4%)。 所有4例严重vod患者最终都会屈服于疾病。 在多变量分析中,i.v. 与每种OS给药相比,Bu的施用与显着降低的VOD发病率有关。 总之,VOD仍然是使用含有BU的RIC方案的Allo-Sct严重并发症。 虽然严重vod的发病率非常低,但严重VOD患者组的总体死亡率仍然非常高,因此需要新的处理方法。

著录项

  • 来源
    《Bone marrow transplantation》 |2014年第11期|共4页
  • 作者单位

    Hadassah Hebrew University Medical Center Bone Marrow Transplantation and Cancer Immunotherapy;

    Hadassah Hebrew University Medical Center Bone Marrow Transplantation and Cancer Immunotherapy;

    Hadassah Hebrew University Medical Center Bone Marrow Transplantation and Cancer Immunotherapy;

    Hadassah Hebrew University Medical Center Bone Marrow Transplantation and Cancer Immunotherapy;

    Hadassah Hebrew University Medical Center Bone Marrow Transplantation and Cancer Immunotherapy;

    Hadassah Hebrew University Medical Center Bone Marrow Transplantation and Cancer Immunotherapy;

    Hadassah Hebrew University Medical Center Bone Marrow Transplantation and Cancer Immunotherapy;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号